Tirzepatide reaches its NCE-1 date, opening the door to generic filings

May 13, 2026, marked tirzepatide's NCE-1 date — four years after Mounjaro's May 2022 approval — the first day generic drugmakers can file an abbreviated new drug application (ANDA) with a Paragraph IV certification challenging Eli Lilly's Orange Book patents on the drug ^[1][2]. This is a procedural opening, not a market change. Tirzepatide's New Chemical Entity (NCE) exclusivity, a separate statutory FDA protection, does not expire until May 13, 2027, so the agency cannot approve any generic ANDA before that date even if one is filed today ^[1][2].

The patent picture behind that date is layered. The core compound patent, US 9,474,780, covers the GIP/GLP-1 co-agonist molecule itself. One source lists its expiry as January 5, 2036 ^[1], while a patent-tracking database lists it as May 2036 ^[2] — the sources disagree on the exact month, though both put it in 2036. Beyond that compound patent, Lilly has added formulation and method-of-use patents that run much longer: US 12,295,987 for Mounjaro is listed through December 30, 2041, and US 12,343,382 and related patents for Zepbound run through July 22, 2039 ^[1][2]. A patent-tracking service estimates Zepbound's realistic generic launch date at July 22, 2039, based on this portfolio ^[2]. Independent analysts cited by one source put the earliest plausible US launch at 2036, with 2039 to 2041 seen as more likely once trailing patents are factored in ^[1].

Zepbound alone carries ten US patents filed between 2023 and 2026, none of which have expired ^[2]. Challenges to the core '780 patent were already underway before the NCE-1 date: Empower Clinic Services filed a patent-office challenge in May 2025 that was denied on procedural grounds in October 2025, and a group including BPI Labs filed a similar challenge in August 2025 that was denied in December 2025 ^[2]. Neither challenge succeeded, and both were administrative petitions rather than the ANDA process that just became available. Zepbound also holds additional FDA exclusivities tied to specific uses, including a New Product exclusivity to November 8, 2026, and a sleep apnea indication exclusivity to December 20, 2027 ^[2]. Under FDA rules, the first company to file an ANDA with a successful Paragraph IV challenge earns 180 days as the sole generic competitor, which is the incentive driving early filings even though the underlying patents remain years from expiring ^[1].

Why it matters for patients

For people currently taking Mounjaro or Zepbound, this milestone does not change price or availability. It opens a legal door that generic manufacturers can now walk through, but the patents on file mean any resulting generic is realistically years away — plausibly not before 2036, and by some estimates not until 2039 to 2041 ^[1][2]. Patients budgeting for long-term treatment should not expect a cheaper tirzepatide option to appear soon. In the meantime, cost-lowering options for GLP-1 treatment generally include negotiated Medicare prices for semaglutide products, a newly available generic liraglutide, and compounded versions — though each comes with its own limits and, in the case of compounding, safety questions not addressed by FDA approval ^[1].

What happens next

Watchers of the patent record will be looking for whether any generic manufacturer files a Paragraph IV ANDA now that the door is open, and how Lilly responds; such litigation, if filed, typically triggers an automatic stay of FDA approval. The next fixed date is May 13, 2027, when tirzepatide's NCE exclusivity expires and the FDA becomes free to approve a generic ANDA if one has cleared the underlying patent challenges ^[1][2]. Given the compound patent's 2036 expiration and trailing formulation patents into 2039 and beyond, most analysts do not expect an actual generic launch before then absent a successful early patent challenge ^[1][2].